Compare IDAI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDAI | GDTC |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 12.1M |
| IPO Year | 2022 | 2021 |
| Metric | IDAI | GDTC |
|---|---|---|
| Price | $2.05 | $0.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 104.9K | 12.0K |
| Earning Date | 05-15-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $103.06 | N/A |
| Revenue Next Year | $140.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $0.68 |
| 52 Week High | $5.28 | $3.68 |
| Indicator | IDAI | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 48.76 | 44.33 |
| Support Level | $1.90 | $0.92 |
| Resistance Level | $2.52 | $1.07 |
| Average True Range (ATR) | 0.20 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 55.13 | 32.71 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The company operates in one reportable segment, artificial intelligence-powered solutions. The artificial intelligence-powered solutions segment generates revenue from software licenses, professional services, and recurring SaaS revenue.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.